- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Retrospective, Multicentre
- Study aim: To assess the effectiveness of sotrovimab versus no early COVID-19 treatment in highest-risk COVID-19 patients during Omicron predominance
- Number of participants enrolled: 5790
- Study enrolling from to
- Study includes follow-up for 4 weeks
- Standardisation: SNOMED, ICD-10
Study Data
- Adults
- Paediatric
- Elderly
- Immunocompromised host
- Fragile population
- Outpatient clinic
- Non-hospital health centre
- Community
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Monoclonal antibodies
- Sotrovimab
External Links
Other information
Funders:
- GSK|Vir Biotechnology
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to